Insider Trading Alert - OPK, SWKS And DORM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 24, 2014, 69 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $101.08 to $41,000,000.00.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al, who is CEO & Chairman at Opko Health, bought 36,300 shares at $8.17 on April 24, 2014. Following this transaction, the CEO & Chairman owned 140.5 million shares meaning that the stake was reduced by 0.03% with the 36,300-share transaction.

The shares most recently traded at $8.07, down $0.10, or 1.22% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.1 million shares per day over the past 30 days. Opko Health has a market cap of $3.4 billion and is part of the health care sector and health services industry. Shares are down 2.37% year-to-date as of the close of trading on Thursday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently, there are 4 analysts who rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Skyworks Solutions (SWKS) - FREE Research Report

Mclachlan David J, who is Director at Skyworks Solutions, sold 2,000 shares at $39.41 on April 24, 2014. Following this transaction, the Director owned 57,315 shares meaning that the stake was reduced by 3.37% with the 2,000-share transaction.

The shares most recently traded at $41.22, up $1.81, or 4.39% since the insider transaction. Historical insider transactions for Skyworks Solutions go as follows:

  • 4-Week # shares sold: 3,256
  • 12-Week # shares sold: 3,256
  • 24-Week # shares sold: 391,736

The average volume for Skyworks Solutions has been 3.5 million shares per day over the past 30 days. Skyworks Solutions has a market cap of $7.9 billion and is part of the technology sector and electronics industry. Shares are up 47.62% year-to-date as of the close of trading on Thursday.

Skyworks Solutions, Inc., together with its subsidiaries, provides analog semiconductors worldwide. The company has a P/E ratio of 23.4. Currently, there are 11 analysts who rate Skyworks Solutions a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWKS - FREE

TheStreet Quant Ratings rates Skyworks Solutions as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Skyworks Solutions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Dorman Products (DORM) - FREE Research Report

Berman Steven L, who is Chief Executive Officer at Dorman Products, sold 7,700 shares at $58.05 on April 24, 2014. Following this transaction, the Chief Executive Officer owned 1.3 million shares meaning that the stake was reduced by 0.59% with the 7,700-share transaction.

The shares most recently traded at $56.71, down $1.34, or 2.35% since the insider transaction. Historical insider transactions for Dorman Products go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares sold: 7,000

The average volume for Dorman Products has been 302,300 shares per day over the past 30 days. Dorman Products has a market cap of $2.1 billion and is part of the consumer goods sector and automotive industry. Shares are up 3% year-to-date as of the close of trading on Thursday.

Dorman Products, Inc. supplies automotive replacement parts, automotive hardware, brake products, and household hardware to the automotive aftermarket and mass merchandise markets. The company has a P/E ratio of 26.3. Currently, there are 4 analysts who rate Dorman Products a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DORM - FREE

TheStreet Quant Ratings rates Dorman Products as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Dorman Products Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Biotech Movers: Paratek, Opko, Endo

Biotech Movers: Paratek, Opko, Endo